Harry Oken
Internal Medicine · Columbia, MDNPI 1679566160
Payments from drug & device makers
Across 110 payments — averaging $18.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$344
- Amgen$322
- AbbVie$173
- QOL Medical, LLC$162
- Radius Health, Inc.$137
- Novo Nordisk$131
- plus $806 from 14 others
What the payments were for
- Food & beverage$2,075100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 18 | $344 |
| Amgen | 19 | $322 |
| AbbVie(2 entities) | 9 | $173 |
| QOL Medical, LLC | 7 | $162 |
| Radius Health, Inc. | 7 | $137 |
| Novo Nordisk | 9 | $131 |
| Exact Sciences | 6 | $130 |
| AstraZeneca | 6 | $121 |
| GSK | 5 | $97 |
| Lilly USA, LLC | 5 | $87 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $80 |
| Johnson & Johnson(2 entities) | 5 | $77 |
| Boehringer Ingelheim | 3 | $57 |
| Novartis | 1 | $33 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $25 |
| Aimmune Therapeutics, Inc. | 1 | $25 |
| Regeneron Healthcare Solutions, Inc. | 2 | $25 |
| Idorsia Pharmaceuticals US Inc | 1 | $22 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Arbor Pharmaceuticals, Inc. | 1 | $11 |
How this compares
$2,075 in reported general payments places this provider in the 80th percentile of 2,979 internal medicine providers in Maryland.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 72 | $98,628 |
| MounjaroTirzepatide | 59 | $74,599 |
| JardianceEmpagliflozin | 41 | $47,524 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 32 | $32,089 |
| Repatha SureclickEvolocumab | 33 | $29,980 |
| OzempicSemaglutide | 21 | $26,626 |
| XareltoRivaroxaban | 12 | $19,790 |
| RybelsusSemaglutide | 12 | $11,686 |
| Rosuvastatin Calcium | 291 | $4,047 |
| Ezetimibe | 59 | $2,296 |
| SynthroidLevothyroxine Sodium | 30 | $1,707 |
| Escitalopram Oxalate | 81 | $1,676 |
| Atorvastatin Calcium | 142 | $1,597 |
| Bupropion XlBupropion Hcl | 24 | $1,428 |
| Amlodipine Besylate | 100 | $1,379 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $344 | $98,62872 claims |
| Lilly USA, LLCMounjaro | $87 | $74,59959 claims |
| Boehringer IngelheimJardiance | $57 | $47,52441 claims |
| Novo NordiskOzempic, Rybelsus | $131 | $38,31133 claims |
| GSKTrelegy Ellipta | $97 | $32,08932 claims |
| Johnson & JohnsonXarelto | $77 | $19,79012 claims |
| AbbVieSynthroid | $173 | $1,70730 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,979 internal medicine providers in Maryland.
Other internal medicine in Columbia
- Mark CorriereColumbia$402K
- Saba SheikhColumbia$342K
- William SawayColumbia$295K
- Shishir KhetanRockville$52.1M
- Steven GellerElkridge$15.1M
- Mary HowellHagerstown$6.2M
- Kristen MarroneBaltimore$5.6M
- Jonathan CohenRockville$5M
- Andrea ApoloBethesda$4.8M
- Peta-Gay Jackson BoothBaltimore$3.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.